Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
05/02/16Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress
– Advances Pipeline of Ten Clinical Stage Programs, with Ten Additional Clinical Data Readouts Anticipated This Year – – Expects to Complete Enrollment of Revusiran Phase 3 ENDEAVOUR Trial in Late 2016 with Data Readout in Mid-2018 – – On Track to Start Fitusiran Phase 3 Program in Mid-2016; Plans to Report Updated Hemophilia Patient Data in July – – Provides Update on ALN-CC5 Program and Development Path Forward; Plans to ... 
Printer Friendly Version
04/28/16Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts
– 200,000 Square Foot State-of-the-Art Manufacturing Facility Supports Expanding Development Pipeline and Transition Toward Commercial Stage – – Facility Expected to be Operational in 2018 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 28, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will break ground today on a state-of-the-art biopharmaceutical manufacturing fac... 
Printer Friendly Version
04/26/16Alnylam to Webcast Presentations at Upcoming May Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Deutsche Bank 41st Annual Health Care Conference on Wednesday, May 4, 2016 at 8:40 am ET at the InterContinental Hotel in Boston, Massachusetts, and at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 201... 
Printer Friendly Version
04/25/16Alnylam to Webcast Conference Call Discussing First Quarter 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 25, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2016 on Monday, May 2, 2016, after the U.S. financial markets close. Management will provide an update on the company, discuss first quarter 2016 results, and discuss expectations for the future via conference ... 
Printer Friendly Version
04/20/16Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
– Patisiran Achieves a Mean 0.8 Point Decrease in Modified Neuropathy Impairment Score (mNIS+7) at 18 Months, Showing Continued Evidence of Potential Halting of Neuropathy Progression – – Company Reports First-Ever Clinical Correlative Evidence that the Degree of TTR Knockdown May Be Associated with Improvement in mNIS+7 – – Company to Host Conference Call Today, Wednesday, April 20, at 8:30 am ET to Discuss Results – C... 
Printer Friendly Version
04/06/16Alnylam to Webcast Presentation at 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 6, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 3:00 pm ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the co... 
Printer Friendly Version
03/14/16Alnylam Initiates Fitusiran (ALN-AT3) Dosing in Hemophilia A and B Patients with Inhibitors in Ongoing Phase 1 Study
– Company Reinforces Global Commitment to Patients with Hemophilia During Bleeding Disorders Month – – Fitusiran Phase 3 Initiation Remains on Track for Mid-2016 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 14, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has initiated dosing of hemophilia patients with inhibitors in Part D of an ongoing Phase 1 clinical trial ev... 
Printer Friendly Version
03/09/16Alnylam Initiates Phase 1/2 Clinical Trial for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
– Expects to Report Initial Clinical Activity Data in Late 2016 – – Receives Both U.S. and EU Orphan Drug Designations – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-GO1, a subcutaneously administered investigational RNAi therapeutic for the treatment of Primary Hyper... 
Printer Friendly Version
02/29/16Alnylam to Webcast Presentations at Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 29, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 36th Annual Healthcare Conference on Monday, March 7, 2016 at 3:20 pm ET at the Boston Marriott Copley Place Hotel in Boston, Massachusetts, as well as the Barclays Global Healthcare Conference on Tuesday, March 15, 2016 ... 
Printer Friendly Version
02/11/16Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress
– Advanced Pipeline of Eight Clinical Stage Programs in 2015, with Ten or More Major Clinical Data Readouts, Start of Fitusiran Phase 3 Trials, and Three New IND Filings Planned in 2016 – – Completed Enrollment in Patisiran Phase 3 APOLLO Trial, Positioning the Company for First Filing for Regulatory Approval in 2017 – – Maintained Strong Balance Sheet with $1.28 Billion in Cash and Expects to End 2016 with Greater than $850 Million in Ca... 
Printer Friendly Version
02/04/16Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2015 on Thursday, February 11, 2016, after the U.S. financial markets close. Management will provide an update on the company, discuss fourth quarter and year-end 2015 results, and discuss expectations ... 
Printer Friendly Version
02/01/16Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
– Company Remains on Track to File New Drug Application in 2017 without Interim Analysis for Efficacy – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has completed enrollment – with well over 200 patients accrued – in its APOLLO Phase 3 study with patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for ... 
Printer Friendly Version
02/01/16Alnylam to Webcast Presentations at Upcoming February Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 3:00 pm ET as well as the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 pm ET, both at the Waldorf Astoria in New Yor... 
Printer Friendly Version
01/11/16Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline
– Company Plans to Advance Multiple Phase 3 Programs, Including Start of Two Fitusiran Phase 3 Studies, and Expects Ten or More Major Clinical Data Readouts and Three New IND Filings – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today its pipeline goals for 2016 across its Genetic Medicine, Cardio-Metabolic Disease, and Hepatic Infectious Dise... 
Printer Friendly Version
01/04/16Alnylam to Webcast Presentation at 34th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 10:00 am PT (1:00 pm ET) at The Westin St. Francis in San Francisco. This presentation will include a review of the company’s goals and guidance. In addition, the compan... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.